Faslodex (fulvestrant), a new drug for metastatic breast cancer

June 2002

You'll start hearing about Faslodex (fulvestrant), a new drug for metastatic breast cancer.

It's awaiting approval in Canada...and just became available in the U.S.

Faslodex is a once-monthly injection to treat postmenopausal women whose cancer progresses on tamoxifen or another antiestrogen.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

patients to think that antidepressant drugs don't work any better than placebo
whether the COX-2 inhibitors really cause fewer GI problems than traditional NSAIDs
Infectious Diseases increasing resistance of strep throat to macrolides
Infectious Diseases quinolone-resistant gonorrhea is on the rise
Ophthalmology Rescula (unoprostone), a new eyedrop for glaucoma
Osteoporosis Actonel (risedronate) will soon come in a new 35 mg tablet for once-a-week dosing
New guidelines will help clarify how to treat bipolar disorder
Paxil is now approved for post-traumatic stress disorder...TAPER the dose of Paxil when discontinued
Anticoagulants new IV anticoagulant called Argatroban (argatroban)
Hematology & Oncology recommends AVOIDING routine use of HRT in women who have had breast cancer
Hematology & Oncology Faslodex (fulvestrant), a new drug for metastatic breast cancer
Women's Health many women are asking how to discontinue HRT
Women's Health two new alternatives to oral contraceptives
Natural Medicines coenzyme Q10 to PREVENT migraines
Diabetes recent media reports that "metformin is dangerous."
Gastroenterology the approval of restricted use of Lotronex